Soluble serum interleukin-2 receptor, interleukin-6 and interleukin-1a in patients with endometriosis and in controls.
The aim of this study was to verify to what extent danazol alters cell-mediated immunity. To this end, cell-mediated immunity was studied in 10 infertile patients with endometriosis and in 10 normal controls. Nonspecific parameters studied included serum SIL-2R, IL-6 and IL-1a levels. We also investigated the effect of treatment with Danazol on the levels of SIL-2R, IL-6 and IL-1a in women with endometriosis. Blood SIL-2R, IL-6 and IL-1a levels were measured in endometriotic women before treatment, during the last fifteen days of a 6-months course of Danazol and three months after treatment. Only one blood sample was taken from 10 women without endometriosis. SIL-2R, IL-6 and IL-1a levels were higher in women with endometriosis before treatment compared with controls. Administration of the drug significantly reduced the levels of SIL-2R (P < 0.001), IL-6 (P < 0.05) and IL-1a (P < 0.01). Our findings suggest that endometriosis is a condition which induces a rise in interleukin levels. Danazol also appears significantly to reduce endometriosis-associated autoimmune abnormalities.
Koumantakis
E
E
Department of Obstetrics and Gynecology, University Hospital, Iraklion, Crete, Greece.
Matalliotakis
I
I
Neonaki
M
M
Froudarakis
G
G
Georgoulias
V
V
D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D004715:Endometriosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007247:Infertility, Female / Q000188:drug therapy / Q000276:immunology; D007375:Interleukin-1 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000187:drug effects* / Q000378:metabolism
D007375:Interleukin-1; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D003613:Danazol